New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:48 EDTLGND, ONXXLigand Pharma should benefit significantly from Onyx drug, says Roth Capital
After Onyx (ONXX) reported $18.6M in Kyprolis sales for Q3, Roth Capital notes that Ligand (LGND) receives a 3% average royalty on Kyprolis sales. The firm believes that Kyprolis will help enable Ligand to rapidly become profitable and it maintains a $25 target and Buy rating on the stock.
News For LGND;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
07:41 EDTLGNDEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 10, 2015
09:15 EDTLGNDLigand management to meet with Deutsche Bank
Subscribe for More Information
09:06 EDTLGNDLigand amends Master License Agreement with Viking Therapeutics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use